Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Chief Financial Officer | July 15, 2023 | July 19, 2023 |
| NORTECH SYSTEMS INCNSYS · Entity 7417 | CHIEF FINANCIAL OFFICER | December 04, 2023 | December 05, 2023 |
| Vyant Bio, Inc.VYNT · Entity 116415 | Chief Financial Officer | March 15, 2022 | March 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KORU Medical Systems, Inc.
Report date July 15, 2023 · Filed July 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2033-07-15 | Direct | 300,000 |
Reported balance
After 2023-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-15 · Grant · Acquired 300,000 · Balance 300,000 F1: Nonqualified stock options granted as an inducement to employment . Options vest in increments of 75,000 on the first anniversary of the date of grant and each anniversary thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Nonqualified stock options granted as an inducement to employment . Options vest in increments of 75,000 on the first anniversary of the date of grant and each anniversary thereafter until fully vested.
NORTECH SYSTEMS INC
Report date December 04, 2023 · Filed December 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.04 · Expires 2033-12-03 | Direct | 40,000 |
Reported balance
After 2023-12-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-04 · Grant · Acquired 40,000 · Balance 40,000 F1: Represents 40,000 Options granted on December 4, 2023, vesting in equal installments of 8,000 Options on each of December 4, 2024, December 4, 2025, December 4, 2026, December 4, 2027 and December 4, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 40,000 Options granted on December 4, 2023, vesting in equal installments of 8,000 Options on each of December 4, 2024, December 4, 2025, December 4, 2026, December 4, 2027 and December 4, 2028.
Vyant Bio, Inc.
Report date March 15, 2022 · Filed March 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2032-03-15 | Direct | 110,000 |
Reported balance
After 2022-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-15 · Grant · Acquired 110,000 · Balance 110,000 F1: The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SkyWater Technology, LLC
Report date July 31, 2026 · Filed July 31, 2026
Section 16 reporting ended · disclosed 2026-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-31 · Disposition to issuer · Disposed 11,428 · Balance 0 F1: Represents shares of common stock of SkyWater Technology, Inc. ("SkyWater") disposed of pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 25, 2026, by and among SkyWater, IonQ, Inc. ("IonQ"), Merger Subsidiary 1 Inc. ("Merger Subsidiary 1"), and Iris merger Subsidiary 2 LLC (now known as SkyWater Technology, LLC) ("Surviving Company"), including the merger of Iris Merger Subsidiary 1 with and into Surviving Company (the "Second Merger"). At the effective time of the First Merger (the "Effective Time"), each share of SkyWater common stock outstanding immediately prior to the Effective Time (subject to certain exceptions described in the Merger Agreement) automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-31 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-31 · Disposition to issuer · Disposed 4,304 · Balance 0 F2: Represents restricted stock units relating to shares of SkyWater common stock. Pursuant to the Merger Agreement, prior to the Effective Time, each award of restricted stock units relating to shares of SkyWater common stock held by a non-employee member of SkyWater's board of directors that was outstanding, whether vested or unvested, automatically became fully vested and settled in shares of SkyWater common stock. At the Effective Time, each share of SkyWater common stock automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of SkyWater Technology, Inc. ("SkyWater") disposed of pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 25, 2026, by and among SkyWater, IonQ, Inc. ("IonQ"), Merger Subsidiary 1 Inc. ("Merger Subsidiary 1"), and Iris merger Subsidiary 2 LLC (now known as SkyWater Technology, LLC) ("Surviving Company"), including the merger of Iris Merger Subsidiary 1 with and into Surviving Company (the "Second Merger"). At the effective time of the First Merger (the "Effective Time"), each share of SkyWater common stock outstanding immediately prior to the Effective Time (subject to certain exceptions described in the Merger Agreement) automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares.
F2: Represents restricted stock units relating to shares of SkyWater common stock. Pursuant to the Merger Agreement, prior to the Effective Time, each award of restricted stock units relating to shares of SkyWater common stock held by a non-employee member of SkyWater's board of directors that was outstanding, whether vested or unvested, automatically became fully vested and settled in shares of SkyWater common stock. At the Effective Time, each share of SkyWater common stock automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Jul 31, 2026 14:40 UTC | SkyWater Technology, LLC SKYT · Entity 27424 | Disposition to issuerCommon Stock | 4,304 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001850633-26-000004 · wk-form4_1785508844.xml · nonDerivative · entry 2 LaFrence Andrew D.C. · CIK 0001850633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: Represents restricted stock units relating to shares of SkyWater common stock. Pursuant to the Merger Agreement, prior to the Effective Time, each award of restricted stock units relating to shares of SkyWater common stock held by a non-employee member of SkyWater's board of directors that was outstanding, whether vested or unvested, automatically became fully vested and settled in shares of SkyWater common stock. At the Effective Time, each share of SkyWater common stock automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares. F2 · price: Represents restricted stock units relating to shares of SkyWater common stock. Pursuant to the Merger Agreement, prior to the Effective Time, each award of restricted stock units relating to shares of SkyWater common stock held by a non-employee member of SkyWater's board of directors that was outstanding, whether vested or unvested, automatically became fully vested and settled in shares of SkyWater common stock. At the Effective Time, each share of SkyWater common stock automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares. Read SEC document |
| July 31, 2026 Filed Jul 31, 2026 14:40 UTC | SkyWater Technology, LLC SKYT · Entity 27424 | Disposition to issuerCommon Stock | 11,428 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001850633-26-000004 · wk-form4_1785508844.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Represents shares of common stock of SkyWater Technology, Inc. ("SkyWater") disposed of pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 25, 2026, by and among SkyWater, IonQ, Inc. ("IonQ"), Merger Subsidiary 1 Inc. ("Merger Subsidiary 1"), and Iris merger Subsidiary 2 LLC (now known as SkyWater Technology, LLC) ("Surviving Company"), including the merger of Iris Merger Subsidiary 1 with and into Surviving Company (the "Second Merger"). At the effective time of the First Merger (the "Effective Time"), each share of SkyWater common stock outstanding immediately prior to the Effective Time (subject to certain exceptions described in the Merger Agreement) automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares. F1 · price: Represents shares of common stock of SkyWater Technology, Inc. ("SkyWater") disposed of pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 25, 2026, by and among SkyWater, IonQ, Inc. ("IonQ"), Merger Subsidiary 1 Inc. ("Merger Subsidiary 1"), and Iris merger Subsidiary 2 LLC (now known as SkyWater Technology, LLC) ("Surviving Company"), including the merger of Iris Merger Subsidiary 1 with and into Surviving Company (the "Second Merger"). At the effective time of the First Merger (the "Effective Time"), each share of SkyWater common stock outstanding immediately prior to the Effective Time (subject to certain exceptions described in the Merger Agreement) automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:09 UTC | SkyWater Technology, LLC SKYT · Entity 27424 | GrantCommon Stock | 4,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001850633-26-000002 · wk-form4_1781298561.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,732 F1 · kind: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the date immediately preceding the next occurring annual meeting of the Issuer's stockholders, contingent on the reporting person's continued service on such vesting date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 15:35 UTC | SkyWater Technology, LLC SKYT · Entity 27424 | GrantCommon Stock | 11,428 | $8.75 | $99,995.00 |
DisclosureSEC source: 0001850633-25-000009 · wk-form4_1748014527.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,428 F1 · kind: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the date immediately preceding the next occurring annual meeting of the Issuer's stockholders, contingent on the reporting person's continued service on such vesting date. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 22:22 UTC | NORTECH SYSTEMS INC NSYS · Entity 7417 | GrantOptions · Derivative | 40,000 | $9.04 Strike: $9.04 | $361,600.00 |
DisclosureSEC source: 0001415889-23-015887 · form4-12052023_101224.xml · derivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-12-03 F1 · derivative.exercise_date: Represents 40,000 Options granted on December 4, 2023, vesting in equal installments of 8,000 Options on each of December 4, 2024, December 4, 2025, December 4, 2026, December 4, 2027 and December 4, 2028. Read SEC document |
| July 15, 2023 Filed Jul 19, 2023 00:52 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantOptions to Purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001161697-23-000419 · form_4.xml · derivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-07-15 F1 · derivative.exercise_date: Nonqualified stock options granted as an inducement to employment . Options vest in increments of 75,000 on the first anniversary of the date of grant and each anniversary thereafter until fully vested. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:15 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantStock option (right to buy) · Derivative | 110,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-22-007155 · ownership.xml · derivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2032-03-15 F1 · derivative.exercise_date: The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 21:05 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 5,000 | $2.00 | $9,997.50 |
DisclosureSEC source: 0001493152-21-029829 · ownership.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,336 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9995 to $2.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| November 23, 2021 Filed Dec 29, 2021 21:30 UTC Amendment | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 5,000 | $2.00 | $9,997.50 |
DisclosureSEC source: 0001493152-21-032696 · ownership.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,292 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9995 to $2.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:05 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 3,000 | $3.28 | $9,837.00 |
DisclosureSEC source: 0001493152-21-012504 · ownership.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,336 Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:24 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001493152-21-007807 · ownership.xml · derivative · entry 5 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires 2031-03-30 F4 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022. Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:24 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | OtherStock option (right to buy) · Derivative | 38,868 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001493152-21-007807 · ownership.xml · derivative · entry 4 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,868 Underlying: Common stock · 38,868 shares Expires 2030-05-22 F3 · kind: Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 38,868 options vest upon the achievement of certain milestones. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 38,868 options vest upon the achievement of certain milestones. Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:24 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | OtherStock option (right to buy) · Derivative | 172,944 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001493152-21-007807 · ownership.xml · derivative · entry 3 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,944 Underlying: Common stock · 172,944 shares Expires 2029-08-30 F2 · kind: Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 111,693 options are currently vested and 61,251 options to vest in equal monthly installments commencing April 30, 2021. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 111,693 options are currently vested and 61,251 options to vest in equal monthly installments commencing April 30, 2021. Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:24 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | OtherCommon Stock, $0.0001 par value | 26,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-007807 · ownership.xml · nonDerivative · entry 2 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 26,866 F1 · kind: Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger. F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger. Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:24 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | OtherCommon Stock, $0.0001 par value | 29,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-007807 · ownership.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,336 F1 · kind: Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger. F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger. Read SEC document |
| March 30, 2021 Filed Jul 13, 2021 13:00 UTC Amendment | Vyant Bio, Inc. VYNT · Entity 116415 | OtherCommon Stock, $0.0001 par value | 26,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-016687 · ownership.xml · nonDerivative · entry 2 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 26,825 F1 · kind: This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") issued pursuant to the merger on March 30, 2021. F1 · price: This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") issued pursuant to the merger on March 30, 2021. Read SEC document |
| March 30, 2021 Filed Jul 13, 2021 13:00 UTC Amendment | Vyant Bio, Inc. VYNT · Entity 116415 | OtherCommon Stock, $0.0001 par value | 29,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-016687 · ownership.xml · nonDerivative · entry 1 LaFrence Andrew D.C. · CIK 0001850633 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,292 F1 · kind: This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") issued pursuant to the merger on March 30, 2021. F1 · price: This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") issued pursuant to the merger on March 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.